hgp1201
Small moleculeexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Sep 1, 2014 (NCT02243319)
Timeline
Indications
Mechanism of action
- Phosphodiesterase 5AINHIBITOR
PDE5A inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- hgp1201
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02715401 | Phase 1 | Oct 1, 2015 | Hanmi Pharmaceutical, Yonsei University |
| NCT02712411 | Phase 1 | Jul 1, 2015 | Hanmi Pharmaceutical, Yonsei University |
| NCT02667938 | Phase 3 | Mar 1, 2015 | Catholic University of Korea, Hanmi Pharmaceutical |
| NCT02243319 | Phase 1 | Sep 1, 2014 | Hanmi Pharmaceutical, University of Ulsan |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hanmi Pharmaceutical | For profit | 4 | 4 | 2 | 2014 |
| Yonsei University | Academic/Hospital | 2 | 0 | 1 | 2015 |
| Catholic University of Korea | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of Ulsan | Academic/Hospital | 1 | 0 | 1 | 2014 |
4 organizations
Page 1 / 1